Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179515 | 0.81 | SLC6A9 (0.36) | NPSR1MAPT | |
| SCHEMBL9853458 | 0.69 | LMNA (0.38) | NPSR1MAPTTSHR | |
| SCHEMBL20221547 | 0.69 | NPSR1 (0.34) | NPSR1MAPT | |
| SCHEMBL5188438 | 0.67 | NPSR1 (0.39) | NPSR1MAPTTSHRALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL29184967 | 0.66 | NPSR1 (0.38) | NPSR1MAPTTSHRALDH1A1L3MBTL1 | |
| SCHEMBL2123016 | 0.66 | NPSR1 (0.32) | NPSR1MAPT | |
| SCHEMBL2125006 | 0.66 | NPSR1 (0.32) | NPSR1MAPT | |
| SCHEMBL25555185 | 0.65 | TSHR (0.33) | TSHR | |
| SCHEMBL3709921 | 0.64 | CYP1A2 (0.36) | NPSR1MAPT | |
| SCHEMBL7458948 | 0.64 | NPSR1 (0.34) | NPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, ZC3HAV1, NR1H4 | NPSR1 2850/4885MAPT 2107/4885TSHR 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.